Loading...
Loading...
Browse all stories on DeepNewz
VisitPercentage of clinical trials meeting diversity guidelines by end of 2024
Below 25% • 25%
25% to 49% • 25%
50% to 74% • 25%
75% or more • 25%
FDA official reports and clinical trial records
FDA Issues Long-Awaited Draft Guidance to Improve Diversity in Clinical Trials for Medical Device Makers
Jun 26, 2024, 02:56 PM
The U.S. Food and Drug Administration (FDA) has issued long-awaited draft guidance to improve diversity in clinical trials. Released six months later than expected, the guidance aims to enhance the representation of racial, ethnic, and other underrepresented groups in clinical studies. This initiative is designed to yield a better understanding of treatment effects, improve clinical trial results, and increase trust and participation among diverse populations. The guidance provides detailed instructions for medical product sponsors and medical device makers on how to submit Diversity Action Plans, which are now required for certain clinical studies.
View original story
Completely ended • 25%
Partially scaled back • 25%
Unchanged • 25%
Expanded • 25%
Implement similar rules • 25%
Rescind existing rules • 25%
No changes • 25%
Other actions • 25%
Increase in diversity • 25%
Decrease in diversity • 25%
No significant change • 25%
Insufficient data • 25%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
No change • 25%
Decrease • 25%
0-25% • 25%
26-50% • 25%
51-75% • 25%
76-100% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
0-10 • 25%
11-20 • 25%
21-30 • 25%
31 or more • 25%
Less than 10% • 25%
10% to 15% • 25%
15% to 20% • 25%
More than 20% • 25%
Technology • 25%
Manufacturing • 25%
Finance • 25%
Healthcare • 25%
Less than 50% • 25%
50% to 75% • 25%
75.1% to 90% • 25%
More than 90% • 25%
GE Healthcare • 25%
Medtronic • 25%
Johnson & Johnson • 25%
Siemens Healthineers • 25%